Search - tctmd.com

Displaying 1 - 20 of 26

Sort: Relevancy | Date

News Daily News

FAME 2 at 10 Years: Less Urgent Revascularization With FFR-Guided PCI

Michael O'Riordan

January 26, 2026

News Daily News

Year in Review: DCBs Big in Coronary News, Along With Beta-blockers in STEMI

Yael L. Maxwell

December 29, 2025

News Daily News

PCI With Intravascular Imaging or Functional Testing Bests Angiography Alone

Michael O'Riordan

November 24, 2023

News Daily News

‘Functional’ SYNTAX Score May Hone PCI, CABG Choices in Multivessel Disease

Michael O'Riordan

September 13, 2023

News Conference News ACC 2022

No Difference in 1-Year QoL Between FFR-Guided PCI and CABG: FAME-3

Michael O'Riordan

April 13, 2022

News Features

FFR’s Future: Negative Trials Spur Debate Over Technology’s Role

Michael O'Riordan

December 23, 2021

News Conference News TCT 2021

FAME 3: PCI Fails to Demonstrate Noninferiority to Surgery in Three-Vessel CAD

Michael O'Riordan

November 04, 2021

News Conference News ESC 2021

FFR During Angiogram Not Beneficial in Chest Pain Patients: RIPCORD 2

Michael O'Riordan

August 29, 2021

News Daily News

In ISCHEMIA, Stable CAD Treatment Effect Hinged on MI Definition

Michael O'Riordan

December 11, 2020

News Daily News

Plaque Burden, Not Coronary Stenosis, Linked to Future Events in Stable CAD

Michael O'Riordan

December 07, 2020

News Daily News

FFR Can Safely Guide PCI Deferral, With Solid Long-term Results: J-CONFIRM

Caitlin E. Cox

January 03, 2020

News Opinion Conversations in Cardiology

Conversations in Cardiology: In the ISCHEMIA Era, What Role for FFR?

January 02, 2020

News

Analysis Hints at Survival Benefit With Revascularization in Stable Patients With Myocardial Ischemia

Michael O'Riordan

September 24, 2019

News Daily News

FARGO: FFR No Help for CABG in Patients With Multivessel Disease

L.A. McKeown

November 27, 2018

News Daily News

ORBITA Redux: Lancet Correspondence Takes Talk of the Sham-Controlled PCI Trial to Further Heights

Michael O'Riordan

July 10, 2018

News Features

Trajectory Unknown: How ORBITA Lands in Clinical Practice Still Up for Debate

Michael O'Riordan

November 27, 2017

Presentation Stanford Coronary Physiology Conference 2017

Fifteen Minutes of FAME

Presenter: William F. Fearon

October 28, 2017

News Conference News AHA 2016

Shaky FUTURE? FFR Takes a Hit With Mortality Signal in French Study

Michael O'Riordan

November 14, 2016

Presentation Stanford Coronary Physiology Conference 2016

Will FFR-Directed PCI Be Better Than CABG? Update on the FAME 3 trial

Presenter: William F. Fearon

October 28, 2016

News Daily News

PLATFORM: FFRCT-Guided Strategy in Suspected CAD ‘Durable’ Out to 1 Year

Michael O'Riordan

July 27, 2016

Advertisement

FAME 2 at 10 Years: Less Urgent Revascularization With FFR-Guided PCI

Year in Review: DCBs Big in Coronary News, Along With Beta-blockers in STEMI

PCI With Intravascular Imaging or Functional Testing Bests Angiography Alone

‘Functional’ SYNTAX Score May Hone PCI, CABG Choices in Multivessel Disease

No Difference in 1-Year QoL Between FFR-Guided PCI and CABG: FAME-3

FFR’s Future: Negative Trials Spur Debate Over Technology’s Role

FAME 3: PCI Fails to Demonstrate Noninferiority to Surgery in Three-Vessel CAD

FFR During Angiogram Not Beneficial in Chest Pain Patients: RIPCORD 2

In ISCHEMIA, Stable CAD Treatment Effect Hinged on MI Definition

Plaque Burden, Not Coronary Stenosis, Linked to Future Events in Stable CAD

FFR Can Safely Guide PCI Deferral, With Solid Long-term Results: J-CONFIRM

Conversations in Cardiology: In the ISCHEMIA Era, What Role for FFR?

Analysis Hints at Survival Benefit With Revascularization in Stable Patients With Myocardial Ischemia

FARGO: FFR No Help for CABG in Patients With Multivessel Disease

ORBITA Redux: Lancet Correspondence Takes Talk of the Sham-Controlled PCI Trial to Further Heights

Trajectory Unknown: How ORBITA Lands in Clinical Practice Still Up for Debate

Fifteen Minutes of FAME

Shaky FUTURE? FFR Takes a Hit With Mortality Signal in French Study

Will FFR-Directed PCI Be Better Than CABG? Update on the FAME 3 trial

PLATFORM: FFRCT-Guided Strategy in Suspected CAD ‘Durable’ Out to 1 Year

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content